Clinical Trial Update: A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating napabucasin plus weekly paclitaxel versus paclitaxel alone in advanced previously treated non-squamous non-small cell lung cancer was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• napabucasin (napabucasin)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2021-06-15